Kymera Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 146.96 million compared to USD 154.81 million a year ago. Basic loss per share from continuing operations was USD 2.52 compared to USD 2.87 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.9 USD | -1.84% | +1.34% | +48.86% |
03/05 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
02/05 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.86% | 2.33B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+46.96% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023